In­di­v­ior snaps up Nar­can own­er for $145M up­front, with an eye on next-gen nasal spray

The opi­oid epi­dem­ic, which kills more than 100,000 peo­ple every year in the US, is big busi­ness, even when it comes to re­vers­ing the ef­fects of an opi­oid over­dose.

UK-based In­di­v­ior on Mon­day bought Opi­ant Phar­ma­ceu­ti­cals, own­er of the now gener­ic opi­oid over­dose an­ti­dote Nar­can and its next-gen nasal spray, a for­mu­la­tion of nalme­fene, which is al­so an opi­oid over­dose re­ver­sal agent. The deal is worth $145 mil­lion up­front and an­oth­er po­ten­tial $80 mil­lion if the nasal spray can­di­date hits cer­tain mile­stones fol­low­ing ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER